Please login to the form below

Not currently logged in
Email:
Password:

Senior changes at EMA

New head of IT and chair of committee for advanced therapies
EMA Dina Tsiambaou

The European Medicines Agency (EMA) has announced changes in leadership for both its IT division and its Committee for Advanced Therapies (CAT).

Dina Tsiambaou (pictured) joins the Agency, which regulates medicines in the EU, as head of the IT development department. She was previously a senior manager in IT at management consultancy Accenture.

In this role she gained experience working in a number of regions, including China, Mauritius, Thailand, Singapore, Turkey, the US, Germany and Ireland.

The EMA's other new appointment was that of Dr Paula Salmikangas as chair of the CAT, the EMA committee responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products.

She was previously vice-chair of the committee and succeeds Christian Schneider, who had chaired the CAT since its creation in 2009.

In addition to her EMA role, Dr Salmikangas is a senior research at the Finnish Medicines Agency.

18th February 2014

From: Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...